Astellas Pharma Inc.
ALPMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $4 | $506 | $459 | $517 |
| % Growth | -99.3% | 10.1% | -11.2% | – |
| Cost of Goods Sold | $1 | $95 | $77 | $99 |
| Gross Profit | $3 | $411 | $382 | $419 |
| % Margin | 73.6% | 81.3% | 83.3% | 81% |
| R&D Expenses | $0 | $72 | $76 | $79 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $197 | $211 | $225 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $48 | $31 | $231 |
| Operating Expenses | $2 | $316 | $319 | $535 |
| Operating Income | $1 | $95 | $64 | -$116 |
| % Margin | 20.5% | 18.7% | 13.8% | -22.5% |
| Other Income/Exp. Net | -$0 | -$4 | -$3 | -$2 |
| Pre-Tax Income | $1 | $90 | $61 | -$118 |
| Tax Expense | $0 | $22 | -$14 | -$21 |
| Net Income | $1 | $68 | $75 | -$98 |
| % Margin | 15.1% | 13.5% | 16.3% | -18.9% |
| EPS | 0.3 | 38.22 | 41.83 | -54.57 |
| % Growth | -99.2% | -8.6% | 176.7% | – |
| EPS Diluted | 0.3 | 38.11 | 41.19 | -54.57 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $4 | $3 | $2 |
| Depreciation & Amortization | $0 | $48 | $48 | $51 |
| EBITDA | $1 | $152 | $102 | $126 |
| % Margin | 29.4% | 30% | 22.2% | 24.4% |